MENZ Tox Shot™ Botox Injection for Erectile Dysfunction in Orlando, FL
If pills have stopped working – or you’re tired of planning your sex life around a 30-minute window – there is a clinically studied alternative. MENZ Tox Shot™ is Dr. J’s proprietary treatment using botulinum toxin (Botox) injected directly into the penis to relax the smooth muscle of penile blood vessels, increase blood flow, and support stronger, more reliable erections.
MENZ Tox Shot™ is a registered trademark of Dr J Anti-Ageing Clinic and is available exclusively at our Orlando location. Every treatment is personally administered by Dr. J — an American Board of Internal Medicine (ABIM) board-certified physician with over 25 years of clinical experience in men’s health and sexual wellness. The protocol is grounded in published peer-reviewed research from journals including Andrology, the Journal of Sexual Medicine, Toxins (Basel), and Sexual Medicine.
This page is written for men who want facts — not hype. The evidence for intracavernosal botulinum toxin in ED is promising and growing, with multiple randomised controlled trials and real-world observational studies now published. It is also an evolving area with important limitations we will explain transparently. Your consultation will cover both sides honestly.
Understanding Erectile Dysfunction What's Actually Happening
Erectile dysfunction is not a character flaw; it is a vascular and neurological event. An erection depends on a highly coordinated process: Sexual arousal triggers the parasympathetic nervous system to release nitric oxide (NO) in the penile tissue. NO causes the smooth muscle cells lining the arteries of the corpus cavernosum, the paired sponge-like chambers that form most of the penis, to relax. As these smooth muscles relax, the penile arteries dilate and blood rushes in. Venous outflow is simultaneously restricted. The result: a firm erection sustained by blood pressure within the corpus cavernosum.
ED occurs when this process breaks down. In vasculogenic ED, the most common organic type, affecting the majority of men over 40, the smooth muscle cells of the penile arteries remain in a state of tonic (semi-permanent) constriction, driven by excess sympathetic nervous system signalling (norepinephrine). The arteries don’t dilate enough, blood inflow is insufficient, and the erection is weak, soft, or unsustained. Oral PDE5 inhibitors (Viagra®, Cialis®) work by amplifying NO signalling — but if the underlying sympathetic over-activity is strong enough or the smooth muscle is too constricted for PDE5-I to overcome, pills fail. This is the physiological gap that MENZ Tox Shot™ targets.
How MENZ Tox Shot™ Works Mechanism of Action
Step 1: Blocking Sympathetic Over-Activity BoNT-A cleaves the SNARE protein SNAP-25, inhibiting the presynaptic release of acetylcholine and, critically, norepinephrine (NE) from adrenergic nerve terminals within the corpus cavernosum. Norepinephrine is the primary sympathetic neurotransmitter that keeps penile smooth muscle contracted. By blocking its release, BoNT-A reduces the tonic vasoconstriction that impedes blood inflow.
Step 2: Smooth Muscle Relaxation and Arterial Dilation With NE suppressed at the local level, cavernosal smooth muscle relaxes and the sinusoidal spaces of the corpus cavernosum dilate. This allows a substantially greater volume of blood to enter and remain in the erectile tissue, producing a firmer, more sustained erection. Doppler ultrasound studies confirm this as objectively measurable increases in Peak Systolic Velocity (PSV), the speed of blood flow through the cavernosal artery following BoNT-A injection.
Step 3: Duration and Persistence Unlike PDE5 inhibitors which last 4–6 hours and require sexual arousal at the time of dosing, BoNT-A’s effect is pharmacologically persistent. After a single injection, the nerve terminals are functionally blocked while new SNAP-25 protein is produced, a process that takes 3 to 6+ months. During this window, the underlying smooth muscle remains in a more relaxed state, supporting improved erectile function throughout, not just around a single dose.
Why This Works When Pills Don’t: The clinical studies specifically target men who have not responded adequately to PDE5 inhibitors (Viagra, Cialis) or alprostadil injections. The rationale is mechanistic: PDE5-Is work downstream; they amplify an existing NO signal. BoNT-A works upstream; it directly reduces the sympathetic tone that prevents smooth muscle relaxation in the first place. These are complementary mechanisms, which is why clinical studies show significant benefit even in men where PDE5-Is alone have failed. They can also be combined.
Potential Benefits of MENZ Tox Shot™
The following benefits reflect what clinical studies have found in responding patients. Individual results vary — not all men achieve the same degree of improvement, and some do not respond. Dr. J’s consultation is designed to assess whether you are likely to be a strong candidate before treatment is recommended.
- Targets the root mechanism of vasculogenic ED: Rather than amplifying a downstream signal (PDE5-Is), BoNT-A reduces the upstream sympathetic constriction that restricts blood flow a mechanistically distinct and complementary approach
- Works when pills have failed: The clinical trials specifically enrolled PDE5-I non-responders and insufficient responders — this is the patient population where the most compelling evidence exists
- Spontaneous sexual activity: — no dosing window — Results, when achieved, are present continuously for the duration of effect (3–9+ months) — not dependent on taking a pill 30–60 minutes before activity
- Improves with repeated treatments: Real-world data shows response rates rising from 67.5% after a 2nd injection to 94.7% after a 4th, suggesting cumulative benefit with a consistent treatment plan
- Favorable safety profile in published literature: Adverse events across all published studies were limited to mild, self-limiting injection-site discomfort in 1.5–6% of patients no systemic serious adverse events reported across any published study
- Can be combined with existing therapies: BoNT-A appears to have a synergistic effect when combined with PDE5-Is; it does not replace other treatments but can augment them
- No systemic side effects from common ED medications: Pills can cause headache, flushing, low blood pressure, vision changes, and interaction with nitrates. Intracavernosal BoNT-A acts locally, without the systemic vascular effects of oral medications
- Minimum downtime: The procedure is performed in-office in 15–30 minutes. Most men return to normal activity the same day with sexual activity resumable after 48–72 hours
What the Clinical Research Shows An Honest Assessment
Design: Prospective, randomized, double-blind, placebo-controlled trial. 176 men with vasculogenic ED who had not responded to PDE5 inhibitors (Viagra/Cialis) or Trimix injections, randomized 1:1:1 to Botox 100U, Botox 50U, or saline placebo, followed for 6 months. Findings: Statistically significant improvement across all outcome measures in both Botox groups vs. placebo: SHIM score, Erection Hardness Score (EHS), Sexual Encounter Profile (SEP), Global Assessment Score (GAS), and Doppler parameters (peak systolic velocity in the cavernosal artery) — all p < 0.001. Maximum improvement at month 3. BTX-100U showed strongest and most durable results. Limitations: Single center (Egypt). The MCID was achieved in approximately 40% of patients — meaningful, but not a majority. Results may not generalize across all ED etiologies.
Design: Randomized controlled trial of botulinum neurotoxin in ED refractory to phosphodiesterase inhibitors. Compared a single intracavernosal injection of BoNT-A against placebo in men who had failed standard PDE5-I therapy. Findings: Significant improvements in SHIM score, EHS, and Doppler ultrasound parameters in the treatment arm. Treatment was well-tolerated. No systemic adverse events were recorded. Adverse events were mild and transient, limited to injection-site discomfort in a small percentage of patients. Limitations: Relatively small sample size; single center; short-to-medium follow-up. Independently replicated El-Shaer's findings.
Design: Retrospective, uncontrolled, single-center study of 123 men with ED insufficient to standard pharmacological therapy (PDE5-Is or PGE1 intracavernosal injections). A single injection of onaBoNT-A 100U or aboBoNT-A 250–500U added to existing treatment. Findings: Clinically meaningful improvement in 50% of patients within approximately 34 days of injection. 41% maintained improvement at approximately 6 months. Only mild, transient injection-site discomfort was reported. No systemic adverse events. Limitations: No control arm; retrospective; single center. Authors themselves noted this as 'preliminary evidence' and called for randomized clinical trials to confirm results.
Design: Real-world observational study tracking men who requested repeated intracavernosal BoNT-A injections for ED unresponsive to approved pharmacological treatments. Findings: Overall response rate of 77.5% across all BoNT-A types (onaBoNT-A, aboBoNT-A, incoBoNT-A) with no statistically significant difference between formulations. Response rate improved with sequential treatments: 67.5% after 2nd injection; 87.5% after 3rd; 94.7% after 4th. Median duration of effectiveness was approximately 9 months. Adverse events were exclusively mild, self-limiting penile discomfort — no systemic events. Limitations: Observational, no control group. All retrospective studies from the same institution (Garches, France). Results require independent replication in larger multicenter RCTs.
Design: PROSPERO-registered systematic review and meta-analysis covering PubMed, Embase, and Medline databases through July 2021. 7 studies were included (5 human, 2 pre-clinical). Meta-analysis performed on EHS, Peak Systolic Velocity (PSV), and SHIM outcomes. Findings: Clear, statistically significant benefit for BoNT-A on PSV (mean difference 10.82 [4.99–16.65], I²=61%) and EHS (mean difference 0.70 [0.47–0.93], I²=94%) vs. placebo/control. Importantly, SHIM score improvement did not reach statistical significance (MD 0.58 [-0.03–1.20], I²=85%). Key nuance: objective vascular measures improved significantly; the self-reported sexual health inventory score improvement was borderline. Limitations: Only 5 human studies were available at the time of analysis; high heterogeneity (I² up to 94%); small total sample sizes.
Design: PRISMA 2020-compliant systematic review and meta-analysis. 61 articles were identified; 6 studies (2 RCTs, 4 retrospective) met inclusion criteria. Most comprehensive published synthesis to date, incorporating all available human evidence. Findings: At least 40% of patients achieved the minimum clinically important difference (MCID) in IIEF-EF/SHIM score. Overall response rate 77.5% when aggregating across all study designs. Statistically significant improvements in SHIM and EHS at 2 weeks post-injection (favouring BoNT-A). Response improved with repeated sessions: 67.5% → 87.5% → 94.7% across 2nd to 4th injections. Adverse effects: mild transient penile pain in 1.5–6% of patients; no systemic serious adverse events. Conclusion: BoNT-A may become an acceptable non-surgical option. However, there is a lack of clinical randomized or observational studies and more randomized studies with standardized reporting are required.' Limitations: Small number of total studies; heterogeneity; most evidence from a single institution.
77.5%
Overall BoNT-A response rate across all formulations
94.7%
Response rate after the 4th injection
session
≥9 mo
Median duration of effectiveness with repeated-injection protocol
1.5–6%
Incidence of adverse events (mild transient penile pain only) — no systemic serious adverse events in any published study
Who Is MENZ Tox Shot™ For?
Potentially Good Candidates:
- Have not responded adequately to oral PDE5 inhibitors (sildenafil/Viagra®, tadalafil/Cialis®, vardenafil/Levitra ®, avanafil/Stendra®)
- Experience significant side effects from oral ED medications that limit their usability
- Have vasculogenic ED, or suspected erectile dysfunction caused by reduced penile arterial blood flow
- Have tried other second-line therapies, including alprostadil (PGE1) intracavernosal injections with insufficient results
- Want a longer-acting solution that supports spontaneous sexual activity without per-encounter dosing
- Are in good general health without contraindications to botulinum toxin injections
- Have realistic expectations: understand this is an emerging treatment with meaningful but not guaranteed success rates
- Are men aged 35–70 with predominantly organic (vascular) rather than psychogenic-only ED
MENZ Tox Shot™ Is Less Likely to Be Recommended If You:
- Have primarily psychogenic ED (anxiety, relationship issues, performance anxiety) without a vascular component: oral medications, therapy, or hormone optimization may be more appropriate first steps
- Have a known hypersensitivity or allergy to botulinum toxin products
- Have an active penile infection, significant penile scarring (Peyronie’s disease with active plaque), or coagulation disorders that cannot be safely managed
- Have not first attempted first-line treatments (oral PDE5-Is) unless medically contraindicated. BoNT-A is typically most compelling as a second-line option
- Are seeking a permanent or curative solution: intracavernosal BoNT-A improves function for the duration of its effect; it does not alter the underlying causes of ED
Not Sure Where You Fall? That is exactly what the free consultation is designed to address. Dr. J will review your medical history, ED history, prior treatments, cardiovascular health, hormonal status, and lifestyle factors to build a complete clinical picture. He will give you his honest medical assessment — including whether MENZ Tox Shot™, a different MENZ treatment, or a combination approach is most likely to produce meaningful results for you specifically. There is no pressure and no obligation.
Your MENZ Tox Shot™ Appointment Step by Step
Every man’s experience is different, and every MENZ Tox Shot™ appointment is personalised to your case. Here is exactly what to expect from first contact through your results timeline.
Step 1: Free Confidential Consultation: Dr J conducts a thorough, private medical intake – no judgement, no embarrassment. He reviews your full medical history, current medications (especially nitrates, blood thinners, or alpha-blockers), cardiovascular history, ED onset and severity, and all prior ED treatments and their outcomes. He explains the procedure, the clinical evidence, its limitations, and alternative MENZ treatments. You leave with a clear picture of whether this is the right fit for you.
Step 2: Medical and Vascular Assessment: Dr J evaluates your vascular health profile — including blood pressure, cardiovascular risk factors (diabetes, hypertension, and hypercholesterolaemia), and hormonal status if not recently assessed. He determines the optimal BoNT-A formulation and dose (typically onabotulinumtoxinA 100 units for the first treatment). Men with a primarily psychogenic component may be referred for additional evaluation or a combined approach.
Step 3: Pre-Procedure Preparation: No specific fasting is required. Inform Dr J of any anticoagulant medications (aspirin, warfarin, and blood thinners). For most men, no medication changes are needed. Arrive in clean, comfortable clothing. The appointment typically takes 30–45 minutes total, including preparation time.
Step 4: Topical Anaesthesia: A topical numbing cream (EMLA or equivalent) is applied to the penis and allowed to take full effect over 15–20 minutes. A penile ring band may be used temporarily during the injection to ensure precise, controlled delivery of the botulinum toxin to the corpus cavernosum. Most men describe their level of anticipatory anxiety as higher than their level of actual procedural discomfort.
Step 5: The Injection: Using an ultra-fine needle, Dr J administers botulinum toxin directly into the corpus cavernosum — the erectile tissue that fills with blood during an erection. The injection volume is small and precisely targeted. The entire injection step takes approximately 5–10 minutes. In published clinical studies, adverse events were limited to mild, transient penile pain or a burning sensation in 1.5–6% of patients. No systemic adverse events have been reported.
Step 6: Immediate Post-Procedure: There is virtually no downtime. The site is briefly assessed, and Dr J provides full post-injection instructions. Most men drive themselves home and return to normal activities the same day. Sexual activity should be avoided for 48–72 hours to allow the botulinum toxin to fully bind to its target nerve terminals before the tissue is under haemodynamic stress.
Step 7: Results Timeline: Early changes in vascular parameters may begin within days, but subjective erection improvement typically becomes noticeable at 2–4 weeks as BoNT-A progressively blocks sympathetic input and smooth muscle tone decreases. Full effect is generally established by 4–6 weeks. Results typically last 3–6 months per treatment based on the RCT data, with real-world observational data showing a median duration closer to 9 months. Dr J will schedule a follow-up assessment and discuss whether a repeat injection course is appropriate.
Step 8: Repeat Treatment Planning: The clinical evidence strongly suggests that repeated injection sessions produce progressively better outcomes—response rates increasing from 67.5% to 94.7% across sequential treatments. Dr J will review your response at your follow-up appointment and develop a personalised maintenance schedule. For optimal results, most men benefit from committing to a structured treatment plan of 3–4 sessions over 12–18 months.
MENZ Tox Shot™ vs. Oral ED Medications Clinical Comparison
MENZ Tox Shot™ (BoNT-A ICI)
Mechanism: Blocks sympathetic NE release smooth muscle relaxation at source
Duration of effect: 3–9+ months per session (continuous)
Spontaneity: No pre-planning effective continuously
Effective for PDE5-I non-responders: Studied specifically in this population different mechanism
Systemic side effects: Minimal local action only; no cardiovascular effects
Cumulative improvement: Evidence of increasing response rate with repeated sessions (67.5% 94.7%)
Evidence level: 2 RCTs + 4 retrospective cohorts + 2 systematic reviews — promising but emerging
Best suited for: Men who have failed pills; vasculogenic ED; men seeking spontaneous activity
Oral PDE5-I (Viagra® / Cialis®)
Mechanism: Inhibits PDE5 enzyme amplifies NO signal vasodilation
Duration of effect: 4–6 hours per pill (sildenafil); 24–36 hours (tadalafil)
Spontaneity: Must take 30–60 min before activity; planned sex only
Effective for PDE5-I non-responders: By definition not effective in non-responders
Systemic side effects: Headache, flushing, nasal congestion, low BP, vision changes; dangerous with nitrates
Cumulative improvement: Consistent per-dose effect; no improvement over time
Evidence level: Extensive RCT data; FDA-approved; AUA first-line treatment
Best suited for: First-line men with mild-moderate ED and intact NO pathway
Alprostadil ICI (Second-Line)
Mechanism: Direct smooth muscle relaxant via cAMP pathway
Duration of effect: 1–2 hours per injection (dose-dependent)
Spontaneity: Must inject before each encounter
Effective for PDE5-I non-responders: Partially but invasive and dose-dependent
Systemic side effects: Priapism risk (prolonged erection requiring treatment); pain; penile fibrosis risk long-term
Cumulative improvement: No evidence of cumulative benefit
Evidence level: FDA-approved; second-line; well-established efficacy in appropriate patients
Best suited for: Men who need reliable erection for specific encounters and have not responded to pills
Explore the Complete MENZ Men's Sexual Wellness Suite
MENZ Tox Shot™ is one component of a comprehensive men’s sexual health and wellness platform designed and offered exclusively by Dr. J. The following treatments can be used independently or combined for a personalised multi-modal program:
MENZ Tox Shot™: Platelet-rich plasma (PRP) injected into penile tissue to stimulate tissue regeneration, improve sensitivity, and support erectile function. Works through a regenerative rather than neuromuscular mechanism.
MENZ Wave®: Low-Low-intensity extracorporeal acoustic wave therapy (Li-ESWT) targeting penile microvasculature by stimulating angiogenesis (new blood vessel formation) and improving vascular health at the tissue level. Addresses the structural vascular component of ED.
MENZ Booster®: Hormone and wellness optimization for testosterone, DHEA, thyroid, and related markers. Low testosterone is a common and underdiagnosed contributor to ED and low libido in men 40+. Optimising hormonal status improves both the baseline and the response to other ED treatments.
MENZ Shot™: PRP injection for sexual health using a slightly different anatomical protocol.
MENZ Grow®: Non-surgical enhancement treatment.
Erectile Dysfunction Comprehensive : full medical assessment of ED aetiology — vascular, hormonal, neurological, and psychogenic components — with a personalised treatment roadmap.
O-Shot® (for women): The female equivalent of regenerative PRP sexual wellness treatment, intravaginal PRP for sexual dysfunction, sensitivity, and urinary incontinence.
